-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medicine Network November 18th, November 17th, the official website of the State Drug Administration shows that Hangzhou Sino-American East China Pharmaceutical injection of sodium totrazolatin through a consistent evaluation of supplementary applications.
2019, China's public medical machine terminals have sales of more than 6 billion yuan in injections, according to the company's internal network.
East China Pharmaceuticals for the variety of the third over-evaluation enterprises.
totraazole is a proton pump inhibitor widely used in clinical applications, mainly used to treat gastritis, stomach erosion, peptic ulcers, reflowal esophagitis, Zoai syndrome and so on.
the main dosage forms of lutonazole, which are currently listed in China, are intestinal tablets, intestinal capsules and injections, of which the largest proportion of injection sales.
China's public medical institutions terminal injection of sodium source: Minet China's public medical institutions terminal competition pattern Mienet data show that in 2019 China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal sodium sodium injection sales exceeded 6 billion yuan; 2020H1 sales of more than 2 billion yuan, Yangzijiang Pharmaceuticals with 28% of the market share ranked first, Hangzhou Sino-American East China Pharmaceuticals with 13% market share followed by the original research manufacturer Takeda with 11.7% of the market share ranked third.
70 domestic enterprises currently have approval for the production of sodium vitolazole for injection, after 18 pharmaceutical companies submitted a consistent evaluation of the product supplementary applications.
Osaikang is the first over-evaluation enterprise for injection of sodium-to-laazole, Yangzijiang Pharmaceutical Group followed closely behind, and East China Pharmaceuticals was the third over-evaluation enterprise of the variety.
with the injection of sodium palladium over-evaluation enterprises gathered 3, it may be included in the future fourth batch of national mining.
source: MiNet Database, NMPA
